Osteoboost Health, today announced it has closed an $8 million financing round to scale manufacturing, expand clinical research, and broaden the commercial reach of the company's FDA-cleared medical device for low bone density. The round was led by Ambit Health Ventures, with participation from new investors including Emmeline Ventures and Disrupt Health Impact Fund, as well as existing investors Esplanade Ventures and Portfolia..

Osteoboost Health 今天宣布已完成 800 万美元的融资，用于扩大生产、拓展临床研究，并推广公司经 FDA 批准的低骨密度医疗器械的商业覆盖。本轮融资由 Ambit Health Ventures 领投，新投资者包括 Emmeline Ventures 和 Disrupt Health Impact Fund，现有投资者 Esplanade Ventures 和 Portfolia 也参与其中。

Osteoboost Health is a company that applies science and medical expertise to create better health outcomes for women and men at risk of osteoporosis and bone fractures. The company's first FDA-approved device, Osteoboost, is poised to become the new standard of care in treating postmenopausal osteopenia..

Osteoboost Health 是一家运用科学和医学专业知识，为面临骨质疏松和骨折风险的女性和男性创造更好健康结果的公司。该公司首个获FDA批准的设备Osteoboost，有望成为治疗绝经后骨量减少的新标准。